uPAR-targeted clustered regularly interspaced short palindromic (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9) gene-editing technology may provide new therapeutic trearments for aggressive cancers. The gene discussed is PLAUR; the disease is cancer.